Navigation Links
From the clinics to the bench and back -- phenytoin as a mood stabilizer?
Date:3/29/2010

This release is available in Chinese.

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties. In a study published in the March 2010 issue of Experimental Biology and Medicine Veronica Mariotti and colleagues utilized DNA microarrays to investigate the molecular underpinnings of the potential mood-stabilizing action of phenytoin by looking at its effect on gene expression in the rat brain.

As compared with untreated animals, rats treated for a month with phenytoin had 508 differentially expressed genes in the hippocampus and 62 in the frontal cortex, including genes involved in GABAergic and glutamatergic neurotransmission, neuroprotection and other genes thought to be crucial for mood regulation. Furthermore, some of these same genes have been shown to be modulated by classical mood-stabilizer agents, like lithium and valproate.

Thus, the findings of this study indicate that chronic phenytoin administration modulates the expression of genes involved in mood regulation and genes that are targets of established mood stabilizers. Dr Mariotti noted that "The results of this study provide preliminary insights into possible molecular mechanisms of action of phenytoin as a potential mood stabilizer and, more in general, the pathophysiology of bipolar disorders".

The study is the product of a fruitful collaboration between the Molecular Biology Laboratory of Dr. Silvia Pellegrini at the Department of Experimental Pathology, University of Pisa Medical School, Pisa, Italy and the Laboratory of Professors Galila Agam and R.H. Belmaker at the Psychiatry Research Unit at the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Mariotti and colleagues have provided very interesting results on the changes in gene expression in rats treated with phenytoin. There findings shed significant light on the mood altering effects of this antiepileptic drug".


'/>"/>

Contact: Dr. Silvia Pellegrini
silvia.pellegrini@bioclinica.unipi.it
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong
2. UC Davis bench-to-bedside research: Promising treatment in clinical trials
3. Animal models that help translate regenerative therapies from bench to bedside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: